The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma

British Journal of Haematology

Volumn 158, Issue 3, 2012, Pages 347-354

  Hockley, Sarah L ^a   Else, Monica ^a   Morilla, Alison ^a   Wotherspoon, Andrew ^a   Dearden, Claire ^a   Catovsky, Daniel ^a   Gonzalez, David ^a   Matutes, Estella ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Hairy cell leukaemia variant; IGHV gene usage; IGHV mutation status; Splenic marginal zone lymphoma; TP53 mutation

Indexed keywords

ALKYLATING AGENT; CLADRIBINE; FLUDARABINE; PENTOSTATIN; RITUXIMAB;

ADULT; AGE; AGED; ANEMIA; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; GENE REARRANGEMENT; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SEQUENCE HOMOLOGY; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; TP53 GENE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, HAIRY CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84863835270     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09163.x     Document Type: Article

References (36)

1. Algara, P., Mateo, M.S., Sanchez-Beato, M., Mollejo, M., Navas, I.C., Romero, L., Solé, F., Salido, M., Florensa, L., Martínez, P., Campo, E. & Piris, M.A. (2002) Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood, 99, 1299-1304.
2. Arcaini, L., Orlandi, E., Scotti, M., Brusamolino, E., Passamonti, F., Burcheri, S., Colombo, N., Vanelli, L., Sbalzarini, G. & Lazzarino, M. (2004) Combination of rituximab, cyclophosphamide and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clinical Lymphoma, 4, 250-252.
3. Arcaini, L., Lazzarino, M., Colombo, N., Burcheri, S., Boveri, E., Paulli, M., Morra, E., Gambacorta, M., Cortelazzo, S., Tucci, A., Ungari, M., Ambrosetti, A., Menestrina, F., Orsucci, L., Novero, D., Pulsoni, A., Frezzato, M., Gaidano, G., Vallisa, D., Minardi, V., Tripodo, C., Callea, V., Baldini, L., Merli, F., Federico, M., Franco, V. & Iannitto, E. ; Integruppo Italiano Linfomi. (2006) Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood, 107, 4643-4649.
4. Arcaini, L., Zibellini, S., Passamonti, F., Rattotti, S., Lucioni, M., Invernizzi, R., Merli, M., Rizzi, S., Boveri, E., Rumi, E., Astori, C., Picone, C., Varettoni, M., Pascutto, C., Paulli, M. & Lazzarino, M. (2009) Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires. Blood Cells, Molecules, & Diseases, 42, 286-291.
5. Bennett, M., Sharma, K., Yegena, S., Gavish, I., Dave, H.P. & Schechter, G.P. (2005) Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica, 90, 856-858.
6. Bikos, V., Darzentas, N., Hadzidimitriou, A., Davis, Z., Hockley, S., Traverse-Glehen, A., Algara, P., Santoro, A., Gonzalez, D., Mollejo, M., Dagklis, A., Gangemi, F., Bosler, D.S., Bourikas, G., Anagnostopoulos, A., Tsaftaris, A., Iannitto, E., Ponzoni, M., Felman, P., Berger, F., Belessi, C., Ghia, P., Papadaki, T., Dogan, A., Degano, M., Matutes, E., Piris, M.A., Oscier, D. & Stamatopoulos, K. (2012) Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia, doi: 10.1038/leu.2012.3 [Epub ahead of print].
7. Brezinschek, H.P., Foster, S.J., Brezinschek, R.I., Dorner, T., Domiati-Saad, R. & Lipsky, P.E. (1997) Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells. Journal of Clinical Investigation, 99, 2488-2501.
8. Brown, J.R., Friedberg, J.W., Feng, Y., Scofield, S., Phillips, K., Dal Cin, P., Joyce, R., Takvorian, R.W., Fisher, D.C., Fisher, R.I., Liesveld, J., Marquis, D., Neuberg, D. & Freedman, A.S. (2009) A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. British Journal of Haematology, 145, 741-748.
9. Chacón, J.I., Mollejo, M., Muñoz, E., Algara, P., Mateo, M., Lopez, L., Andrade, J., Carbonero, I.G., Martínez, B., Piris, M.A. & Cruz, M.A. (2002) Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood, 100, 1648-1654.
10. Cheson, B.D., Sorensen, J.M., Vena, D.A., Montello, M.J., Barrett, J.A., Damasio, E., Tallman, M., Annino, L., Connors, J., Coiffier, B. & Lauria, F. (1998) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. Journal of Clinical Oncology, 16, 3007-3015.
11. Else, M., Dearden, C.E., Matutes, E., Garcia-Talavera, J., Rohatiner, A.Z., Johnson, S.A., O'Connor, N.T., Haynes, A., Osuji, N., Forconi, F., Lauria, F. & Catovsky, D. (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. British Journal of Haematology, 145, 733-740.
12. Flinn, I.W., Kopecky, K.J., Foucar, M.K., Head, D., Bennett, J.M., Hutchison, R., Corbett, W., Cassileth, P., Habermann, T., Golomb, H., Rai, K., Eisenhauer, E., Appelbaum, F., Cheson, B. & Grever, M.R. (2000) Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood, 96, 2981-2986.
13. Gonzalez, D., Martinez, P., Wade, R., Hockley, S., Oscier, D., Matutes, E., Dearden, C.E., Richards, S.M., Catovsky, D. & Morgan, G.J. (2011) Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. Journal of Clinical Oncology, 29, 2223-2229.
14. Goodman, G.R., Burian, C., Koziol, J.A. & Saven, A. (2003) Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. Journal of Clinical Oncology, 21, 891-896.
15. Gruska-Westwood, A.M., Hamoudi, R.A., Matutes, E., Tuset, E. & Catovsky, D. (2001) p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood, 97, 3552-3558.
16. Hockley, S.L., Giannouli, S., Morilla, A., Wotherspoon, A., Morgan, G.J., Matutes, E. & Gonzalez, D. (2010) Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. British Journal of Haematology, 148, 666-669.
17. Hockley, S.L., Morgan, G.J., Leone, P.E., Walker, B.A., Morilla, A., Else, M., Wotherspoon, A., Dearden, C., Catovsky, D., Gonzalez, D. & Matutes, E. (2011) High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia. Leukemia, 25, 1189-1192.
18. Jehn, U., Bartl, R., Dietzfelbinger, H., Haferlach, T. & Heinemann, V. (2004) An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia, 18, 1476-1481.
19. Kalpadakis, C., Pangalis, G.A., Dimitriadou, E., Angelopoulou, M.K., Siakantaris, M.P., Kyrtsonis, M.C., Ximeris, M., Tzenou, T., Sahanas, S., Yiakoumis, X., Papadaki, E.A., Panayiotidis, P. & Vassilakopoulos, T. (2009) Mutation analysis of IGVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome. Anticancer Research, 29, 1811-1816.
20. Kanellis, G., Mollejo, M., Montes-Moreno, S., Rodriguez-Pinilla, S.M., Cigudosa, J.C., Algara, P., Montalban, C., Matutes, E., Wotherspoon, A. & Piris, M.A. (2010) Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica, 95, 1122-1129.
21. Maloisel, F., Benboubker, L., Gardembas, M., Coiffier, B., Divine, M., Sebban, C., Blanc, M., Abgrall, J.F., Lederlin, P., Harousseau, J.L., Blaise, A.M., Grosbois, B., Morice, P., Ghandour, C. & Castaigne, S. (2003) Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia, 17, 45-51.
22. Matutes, E., Wotherspoon, A., Brito-Babapulle, V. & Catovsky, D. (2001) The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia, 15, 184-193.
23. Matutes, E., Oscier, D., Montalban, C., Berger, F., Callet-Bauchu, E., Dogan, A., Felman, P., Franco, V., Iannitto, E., Mollejo, M., Papadaki, T., Remstein, E.D., Salar, A., Solé, F., Stamatopoulos, K., Thieblemont, C., Traverse-Glehen, A., Wotherspoon, A., Coiffier, B. & Piris, M.A. (2008) Splenic marginal zone lymphoma. Proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia, 22, 487-495.
24. Parry-Jones, N., Matutes, E., Gruszka-Westwood, A.M., Swansbury, G.J., Wotherspoon, A.C. & Catovsky, D. (2003) Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. British Journal of Haematology, 120, 759-764.
25. Rinaldi, A., Forconi, F., Arcaini, L., Mian, M., Sozzi, E., Zibellini, S., Baldini, L., Franceschetti, S., Gaidano, G., Marasca, R., Mollejo, M., Piris, M.A., Tucci, A., Facchetti, F., Bhagat, G., Favera, R.D., Rancoita, P.M., Zucca, E., Kwee, I. & Bertoni, F. (2010) Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. British Journal of Haematology, 151, 435-439.
26. Robak, T. (2011) Hairy cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treatment Reviews, 37, 3-10.
27. Ruiz Ballesteros, E., Mollejo, M., Rodriguez, A., Camacho, F.I., Algara, P., Martinez, N., Pollán, M., Sanchez-Aguilera, A., Menarguez, J., Campo, E., Martinez, P., Mateo, M. & Piris, M.A. (2005) Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood, 106, 1831-1838.
28. Salido, M., Baro, C., Oscier, D., Stamatopoulos, K., Dierlamm, J., Matutes, E., Traverse-Glehen, A., Berger, F., Felman, P., Thieblemont, C., Gesk, S., Athanasiadou, A., Davis, Z., Gardiner, A., Milla, F., Ferrer, A., Mollejo, M., Calasanz, M.J., Florensa, L., Espinet, B., Luño, E., Wlodarska, I., Verhoef, G., García-Granero, M., Salar, A., Papadaki, T., Serrano, S., Piris, M.A. & Solé, F. (2010) Cytogenetics aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the splenic B-cell lymphoma Group. Blood, 116, 1479-1488.
29. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, H., Stein, H., Thiele, J. & Vardiman, J. (2008) WHO Classification of Tumours of Haemopoietic and Lymphoid Tissues. IARC, Lyon, France.
30. Thieblemont, C., Felman, P., Callet-Bauchu, E., Traverse-Glehen, A., Salles, G., Berger, F. & Coiffier, B. (2003) Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncology, 4, 95-103.
31. Tierens, A., Delabie, J., Malecka, A., Wang, J., Gruszka-Westwood, A., Catovsky, D. & Matutes, E. (2003) Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations. American Journal of Pathology, 162, 681-689.
32. Traverse-Glehen, A., Baseggio, L., Bauchu, E.C., Morel, D., Gazzo, S., Ffrench, M., Verney, A., Rolland, D., Thieblemont, C., Magaud, J.P., Salles, G., Coiffier, B., Berger, F. & Felman, P. (2008) Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood, 111, 2253-2260.
33. Traverse-Glehen, A., Baseggio, L., Callet-Bauchu, E., Ffrench, M., Coiffier, B., Salles, G., Felman, P. & Berger, F. (2010) Hairy cell leukaemia-variant and splenic red pulp lymphoma: a single entity? British Journal of Haematology, 150, 113-116.
34. Tsimberidou, A.M., Catovsky, D., Schlette, E., O'Brien, S., Wierda, W.G., Kantarjian, H., Garcia-Manero, G., Wen, S., Do, K.A., Lerner, S. & Keating, M.J. (2006) Outcomes in patients with splenic marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer, 107, 125-135.
35. van Dongen, J.J., Langerak, A.W., Brüggemann, M., Evans, P.A., Hummel, M., Lavender, F.L., Delabesse, E., Davi, F., Schuuring, E., García-Sanz, R., van Krieken, J.H., Droese, J., González, D., Bastard, C., White, H.E., Spaargaren, M., González, M., Parreira, A., Smith, J.L., Morgan, G.J., Kneba, M. & Macintyre, E.A. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 17, 2257-2317.
36. Zinzani, P.L., Pellegrini, C., Stefoni, V., Derenzini, E., Gandolfi, L., Broccoli, A., Argnani, L., Quirini, F., Pileri, S. & Baccarani, M. (2010) Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer, 116, 4788-4792.